Last kr98.50 SEK
Change Today -1.25 / -1.25%
Volume 184.0K
MVIRB On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
OTC US
Frankfurt
As of 11:30 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Open
kr98.50
Previous Close
kr99.75
Day High
kr99.50
Day Low
kr97.25
52 Week High
06/12/14 - kr151.00
52 Week Low
12/30/13 - kr82.50
Market Cap
3.1B
Average Volume 10 Days
194.1K
EPS TTM
kr32.14
Shares Outstanding
30.6M
EX-Date
--
P/E TM
3.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

137 Employees
Last Reported Date: 11/20/14

medivir ab-b shs (MVIRB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medivir ab-b shs (MVIRB) Key Developments

Medivir AB Provides Preclinical Data of MIV-802

Medivir AB announced that MIV-802 has been selected as a candidate drug (CD) from its hepatitis C virus (HCV) nucleotide polymerase inhibitor project for the treatment of HCV infection, and is entering non-clinical development. MIV-802 is a highly potent and selective nucleotide inhibitor of the replication of all genotypes of the hepatitis C virus in antiviral assays. Preclinical data indicated that it can be used effectively in combination with other classes of antiviral agents used to treat HCV, including protease inhibitors and NS5A inhibitors. MIV-802 has been designed to deliver large amounts of the drug selectively to the liver, where the hepatitis C virus replicates. Medivir expects to communicate the preclinical antiviral and pharmacokinetic profile of MIV-802 at a major scientific meeting in 2015.

Medivir AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 2014

Medivir AB announced earnings results for the third quarter and nine months ended September 2014. For the quarter, the company reported net turnover of SEK 617.8 million compared to SEK 80.2 million a year ago. Revenues from Medivir's own pharmaceutical sales totalled SEK 100.8 million compared to SEK 36.6 million a year ago. Profit after tax was SEK 373.7 million or SEK 11.83 per diluted share compared to loss after tax of SEK 11.0 million or SEK 0.35 per diluted share a year ago. Cash flow from operating activities amounted to SEK 473.0 million compared to cash flow used in operating activities of SEK 5.2 million a year ago. For the quarter, the company reported net turnover of SEK 1,390.0 million compared to SEK 299.0 million a year ago. Revenues from Medivir's own pharmaceutical sales totalled SEK 210.2 million compared to SEK 210.2 million a year ago. Profit after tax was SEK 985.4 million or SEK 31.21 per diluted share compared to loss after tax of SEK 40.5 million or SEK 1.30 per diluted share a year ago. Cash flow from operating activities amounted to SEK 504.0 million compared to cash flow used in operating activities of SEK 32.5 million a year ago.

Medivir AB Announces U.S. Food and Drug Administration Approved Olysio(R) (simeprevir)

Medivir AB announced that the U.S. Food and Drug Administration (FDA) has approved Olysio(R) (simeprevir) in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C infection in adult patients as part of a combination antiviral treatment regimen. The sNDA was filed in May by Medivir's partner Janssen Research & Development LLC. Data supporting the Olysio(R) and sofosbuvir combination regimen are from the COSMOS study, an open-label, randomized phase II clinical trial that investigated the efficacy and safety of 12 or 24 weeks of Olysio(R) (150 mg once daily) in combination with sofosbuvir (400 mg once daily), with or without ribavirin in HCV genotype 1 chronically infected naïve and treatment-experienced adult patients with compensated liver disease. In the COSMOS study 95% of patients (20/21) with METAVIR F0-F3 (patients with no liver fibrosis to near cirrhotic liver disease) receiving 12 weeks of Olysio(R) with sofosbuvir achieved SVR12 (sustained virologic response 12 weeks after the end of treatment). Regardless of whether patients were treatment-naïve or treatment-experienced 86% of patients (6/7) with METAVIR F4 (cirrhosis) receiving 12 weeks of Olysio(R) in combination with sofosbuvir achieved SVR12, while 100% (10/10) of patients with cirrhosis who were treated with the combination for 24 weeks achieved SVR12. For all patients in the COSMOS trial (treatment-naïve and treatment-experienced, METAVIR F0-F4), 93% (26/28) achieved SVR12 after 12 weeks and 97% (30/31) achieved SVR12 after 24 weeks of treatment. In the COSMOS trial, the most common (> 10%) adverse reactions reported during 12 weeks of treatment with Olysio(R) in combination with sofosbuvir without ribavirin were fatigue (25%), headache (21%), nausea (21%), insomnia (14%) and pruritus (11%). Rash and photosensitivity were reported in 11% and 7% of patients, respectively. During 24 weeks of treatment, dizziness (16%), and diarrhea (16%) were also reported.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr98.50 SEK -1.25

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies
 

Industry Analysis

MVIRB

Industry Average

Valuation MVIRB Industry Range
Price/Earnings 2.8x
Price/Sales 1.8x
Price/Book 1.5x
Price/Cash Flow 2.8x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.